No Data
No Data
Subdued Growth No Barrier To Landfar Bio-medicine Co., Ltd's (SZSE:000504) Price
Nanhua Biotech: 2024 Semi-Annual Report Summary
Nanhua Biotech: 2024 Semi-Annual Report
Landfar Bio-medicine: 2024 Interim Performance Forecast
Even After Rising 17% This Past Week, Landfar Bio-medicine (SZSE:000504) Shareholders Are Still Down 59% Over the Past Three Years
[BT Financial Report Analysis] Landfar Bio-medicine Q1 2024 Report: Comprehensive Analysis of Assets, Liabilities, Profits and Cash Flow.
Landfar Bio-medicine (Stock Code: 000504) is an enterprise that specializes in the biomedical field, particularly with significant advantages in the cell industry. The company is committed to researching and applying advanced medical technologies such as stem cells, immune cells, and gene therapy, and has performed well in the commercialization of cell therapy products. With the deepening of domestic cell therapy research and the expansion of the market scale, Landfar Bio-medicine is expected to continue its leading position in this field. In addition, the company pays attention to the development of energy-saving and environmentally friendly industries, which is in line with the national green development strategy and promotes sustainable development. In the first quarter of 2024, Landfar Bio-medicine's capital...
No Data
No Data